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Abstract: Compared with infections caused by other bacterial pathogens, urinary tract infections (UTIs)
caused by Proteae are often more severe and associated with a higher rate of recurrence, sequelae, and
pyelonephritis. The aim of this retrospective study was to assess and compare the prevalence of UTIs
caused by different species of the Proteae tribe (namely Proteus, Morganella and Providencia species) and
the antibiotic resistance levels isolated from inpatients and outpatients in a primary- and tertiary-care
teaching hospital in the Southern Great Plain of Hungary, during a 10-year study period. To evaluate the
resistance trends of isolated strains, amoxicillin/clavulanic acid, ceftriaxone, meropenem, ertapenem,
gentamicin, ciprofloxacin, and fosfomycin were chosen as indicator antibiotics, based on local
antibiotic utilization data. Members of Proteae were more frequently isolated in the case of inpatients
(7.20 ± 1.74% vs. 5.00 ± 0.88%; p = 0.0031), P. mirabilis was the most frequently isolated member of the
group. The ratio of resistant strains to sulfamethoxazole/trimethoprim, ciprofloxacin, ceftriaxone,
and fosfomycin was significantly higher in the inpatient group. In the case of amoxicillin/clavulanic
acid, ceftriaxone, ciprofloxacin, and sulfamethoxazole/trimethoprim, the ratio of resistant isolates was
markedly higher between 2013–2017 (p < 0.01). Resistance developments of Proteae, coupled with
their intrinsic non-susceptibility to several antibiotics (tetracyclines, colistin, nitrofurantoin) severely
limits the number of therapeutic alternatives, especially for outpatients.
Keywords: urinary tract infection; UTI; antibiotic; resistance; indicator; epidemiology; fosfomycin;
Morganella; Proteus; Providencia
1. Introduction
Urinary tract infections (UTIs) are one of the most common infections in both community
(accounting for 10–30% of infections in primary care) and hospital settings (30–40%) [1–3]. In addition
to their high incidence and diverse spectrum of etiological agents, these infections are often associated
with recurrence, complications, and sequelae, corresponding to a decreased quality of life (QoL) for the
affected patients [1–5]. For this reason, UTIs should be considered as an important factor of morbidity.
The most common causative agents of UTIs are Escherichia coli, Klebsiella spp., Enterococcus faecalis,
members of the Proteae tribe (see below), Pseudomonas aeruginosa, Group B streptococci (GBS),
Staphylococcus saprophyticus, and S. aureus, in addition to Candida spp.; however, the distribution of
etiological agents in UTIs have changed considerably, both in nosocomial and community settings [1–6].
Although there have been developments in novel antimicrobial drugs in the last decade, the treatment
of UTIs is an increasingly complex challenge for clinicians [7]. The growing levels of antibiotic
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resistance (especially in Gram-negative bacteria) severely limits the available treatment options in
these pathologies [8]. Nevertheless, with the emergence of extended-spectrum β-lactamase (ESBL)
and carbapenemase-producing strains in urinary pathogens, multidrug resistance (MDR) is a growing
concern because, when coupled with other inherent and acquired resistance mechanisms, these
pathogens may be resistant to a broad range of antibiotics [9–12].
Most members of the Morganellaceae family (including genera Arsenophonus, Cosenzaea, Moellerella,
Morganella, Photorhabdus, Proteus, Providencia, and Xenorhabdus) are peritrichous Gram-negative rods,
that are ubiquitous in the environment [13–15]. Taxonomically, Morganellaceae are found in the order
Enterobacterales (Gammaproteobacteria), which has been recently re-organized based on comparative
genomic analyses [16]. All human pathogenic members of the Morganellaceae family are found in the
Proteae tribe, comprising of the genera Proteus (including P. hauseri, P. mirabilis, P. myxofaciens, P. penneri,
P. vulgaris, and several yet unnamed genospecies), Morganella (including M. morganii subsp. morganii and
M. morganii subsp. sibonii), and Providencia (including P. alcalifaciens, P. heimbachae, P. rettgerii, P. rustigianii,
and P. stuartii) [13,14]. Species of Proteae are widespread in the environment and are normal inhabitants
of the gut microbiota, in addition, they are the third most frequent causative agents of UTIs, especially in
nosocomial settings [2–4,17]. They are characterized by strong urease production from urine (lowering
the pH, which leads to tissue damage, scarring, and stone formation, through the composition of struvite
and apatite crystals via precipitation of Ca2+ and Mg2+ ions), additionally, they possess virulence factors
crucial for the pathogenesis of UTIs (IgA protease, hemolysin, cytotoxins, and fimbriae) [13,14,17–19].
In contrast to E. coli, Proteae are more frequently isolated in patients with complicated UTIs (i.e., the
presence of urinary catheters and functional or anatomical abnormalities) and are frequently associated
with pyelonephritis, recurrence and prolonged treatment [20–23]. They are intrinsically resistant to
several groups of antibiotics (nitrofurantoin, tetracyclines, and colistin; this intrinsic resistance may be
used as a presumptive identification marker for these organisms), they produce various β-lactamases
(penicillinases, AmpC-β-lactamases) and have an intrinsic reduced susceptibility to imipenem, making
the management of these infections even more difficult [13,14,17–19,24]. It is generally accepted that
P. mirabilis has the most advantageous resistance trends among the Proteae group, while P. vulgaris and
Morganella species have somewhat higher, and Providencia species have the highest rates of resistance
to the relevant antibiotics. Indeed, these differences are frequently used in routine microbiology
laboratories for their phenotypic identification/differentiation [13,14,17–19,24].
Since the 2000s, several national and global (e.g., the SENTRY Antimicrobial Surveillance
Program or the Study for Monitoring Antimicrobial Resistance Trends; SMART) surveillance reports
have evaluated and published the resistance trends of various Gram-positive and Gram-negative
bacteria [25–27]. Nevertheless, there are very few studies available that specifically investigated the
epidemiology and resistance rates of UTIs caused by the tribe Proteae as a whole, despite a trend of
increased resistance in these pathogens having been observed in recent years, with the emergence
of ESBL-producing Proteus species as a particular concern [28–30]. The epidemiology and antibiotic
susceptibility-patterns of urinary tract pathogens vary greatly by region, and, therefore, the assessment
of local data is essential to evaluate trends over time and to reflect on the national situation compared
to international data [31]. Additionally, knowledge of the relevant antibiotic susceptibility patterns
of the major bacterial pathogens for UTIs is of utmost importance to allow for the optimal choice for
antibiotic therapy [32–34].
With this in mind, the aim of this study was to assess and compare the prevalence of UTIs caused
by different species of the Proteae tribe (namely Proteus, Morganella and Providencia species) from
inpatients and outpatients and the antibiotic resistance levels isolated at the Albert Szent-Györgyi
Clinical Center (Szeged, Hungary) retrospectively, during a 10-year study period.
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2. Results
2.1. Demographic Characteristics, Sample Types
The median age of affected patients was 75 years (range: 0.5–98) in the inpatient group with a
female-to-male ratio of 0.83; the age distribution of patients was the following: 8.56% 0–5 years, 6.03%
6–14 years, 18.36% 15–65 years, and 67.05% over 65 years of age. In the outpatient group, the median
age was 57 years (range: 0.5–98) with a female-to-male ratio of 0.91; the age distribution of patients was
the following: 26.19% 0–5 years, 9.87% 6–14 years, 23.42% 15–65 years, and 40.52% over 65 years of age.
The difference in the age distribution of the two patient groups was statistically significant (p < 0.0001).
Most (99.3%) of the samples received from outpatient clinics were voided (midstream) urine, while
the majority (69.38%) from the inpatient departments were catheter-specimen urine; midstream urine
(28.89%) and samples obtained through suprapubic bladder aspiration (1.73%) were less numerous.
2.2. Distribution of Proteae among Inpatient and Outpatient Urine Samples
During the 10-year surveillance period (1st of January 2008–31st of December 2017), the Institute
of Clinical Microbiology received 21,150 urine samples from outpatient clinics and 19,325 positive
samples from inpatient departments that turned out to be positive for a significant urinary pathogen.
From the outpatients, 1058 Proteae isolates were obtained and 1392 from the inpatients. Members of the
Proteae tribe were more frequently isolated in the case of inpatients (7.20 ± 1.74% (range: 3.52–9.56%,
lowest in 2009, highest in 2015) vs. 5.00 ± 0.88% (range: 3.55–6.25%, lowest in 2010, highest in 2017)
of all positive urine samples; p = 0.0031) (Figure 1.). P. mirabilis was the most frequently isolated
member of the group (inpatients: 81.54 ± 2.76% (range: 77.94–85.81%, lowest in 2008, highest in 2012);
outpatients: 82.49 ± 4.76% (range: 74.63–92.11%, lowest in 2010, highest in 2012); p > 0.05), followed by
P. vulgaris (inpatients: 13.24 ± 8.94% (range: 3.38–32.15%, lowest in 2012, highest in 2009); outpatients:
10.82 ± 6.45% (range: 3.95–23.88%, lowest in 2012, highest in 2010); p > 0.05), M. morganii subsp. morganii
(inpatients: 5.07 ± 3.57% (range: 0–12.42%, lowest in 2011, highest in 2013); outpatients: 5.03 ± 3.29%
(range: 0–9.23%, lowest in 2009, highest in 2015); p > 0.05) and Providencia spp., including P. stuartii and
P. rettgerii (inpatients: 1.83 ± 2.72% (range: 0–8.39%, highest in 2017); outpatients: 0.91±0.89% (range:
0–2.63%, highest in 2016); p > 0.05). There were no statistically significant differences in the distribution
of isolates species from inpatient and outpatient samples; however, the ratio of non-Proteus isolates
was much higher in the second half (2013–2017) of the study period in both patient groups (p = 0.018
and p = 0.029, respectively). In 7.28% of inpatients and 8.33% of outpatients, co-infection with another
urinary pathogen was detected (Table 1.), mainly associated with patients over 65 years of age and
urinary catheters (in the case of inpatients). The distribution of co-isolated pathogens corresponds to
the most frequently isolated bacteria in UTIs (e.g., E. coli, K. pneumoniae, E. faecalis). Co-pathogens were
not found in urine samples with Providencia spp.
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The resistance trends of isolated Proteae for amoxicillin/clavulanic acid (AMC) (in the case of
P. mirabilis only), ceftriaxone (CRO), gentamicin (GEN), ciprofloxacin (CIP), and sulfamethoxazole-
trimet oprim (SXT) during the 10-yea surveillance period are presented in Table 2. and Figure 2.
The ratio of resistant strains in the inpatient group was significantly higher to SXT, CIP, and CRO
(p = 0.0025, p < 0.0001, and p = 0.0 71, re pectively), but n t in the ca of GEN (p > 0.05). In contrast,
AMC resistance in P. mirabilis was numerically, but not fi l i r (p = 0.499) in outpatient
samples (going as high as 63.51– 5.68% in th second half of the study period, while this ratio was
49.03–63.23% in the inpatient group). No statistical or numerical differences were observed among the
resistance rates of various Proteae species (i.e., Proteus vs. Pr videncia vs. Morganella; p > 0.05).
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Table 2. Percentage of resistant strains to indicator antibiotics from inpatient and outpatient departments
(2008–2017) a.
Study Period 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Statistics
AMC
R (%) b
Outpatient 12.16 17.57 31.08 60.81 28.38 37.84 63.51 66.22 75.68 62.16 n.s.
(p = 0.499)Inpatient 32.35 37.50 47.17 59.74 56.08 63.23 54.44 56.56 53.13 49.03
CRO R
(%)
Outpatient 4.05 4.11 11.94 27.72 31.58 38.14 25.41 26.15 17.76 24.10
P = 0.0071Inpatient 16.18 23.21 33.02 48.70 47.30 47.10 41.42 40.27 33.75 30.97
GEN R
(%)
Outpatient 10.81 13.70 20.90 10.89 10.53 11.34 15.57 18.46 15.79 17.47 n.s.
(p = 0.32)Inpatient 16.18 14.29 16.04 11.69 20.27 14.19 10.06 23.53 18.75 18.06
CIP R
(%)
Outpatient 8.11 10.96 11.94 23.76 30.26 18.56 27.05 37.69 26.97 37.35
P < 0.0001Inpatient 35.29 26.79 45.28 62.34 56.76 50.97 52.07 43.89 44.38 40.00
SXT R
(%)
Outpatient 28.38 35.62 32.84 45.54 50.00 38.14 59.02 59.23 57.24 57.23
P = 0.0025Inpatient 55.88 50.00 50.94 74.68 68.24 61.94 66.27 64.71 62.50 65.16
a Values in italics represent the lowest (baseline) resistance levels, boldface (peak) values correspond to the highest
resistance levels in the study period; b Corresponding to P. mirabilis susceptibility; n.s.: not significant.
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Figure 2. Resistance levels of Proteae originating from inpatient and outpatient urinary tract infections
AMC resistance levels correspond to P. mirabilis isolates only.
The high incidence of strains resistant to ceftriaxone (>30% of isolates in the inpatient samples,
while ranging between 17.76–38.14% for outpatient samples in the second half of the study period)
peaked in 2011 (48.70%) has been consistent since 2010. Isolates originating from outpatient departments
showed similar growing trends in the survey period. Ciprofloxacin resistance peaked in 2011 for the
inpatient group (62.34%) and has remained above 40% since 2010; while, in the outpatient group,
the peak occurred in 2015 (37.69%). The highest levels of resistance overall were recorded for SXT:
Resistance in inpatient isolates peaked in 2011 (74.68%) and has never gone below 50% in the inpatient
group; in the outpatient group, the peak occurred in 2015 (59.23%) and resistance levels were around
50% since 2011.
The temporal nature of resistance development could also be identified between the first (2008–2012)
and second (2013–2017) half of the study period (p < 0.01) in the case of AMC, CRO CIP, and SXT,
while the resistance levels of GEN has remained the lowest and relatively constant (compared to the
other tested drugs, with 1.5–1.8-fold variation between the baseline and peak resistance) in the 10-year
surveillance period.
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No meropenem- or ertapenem-resistant isolates were recovered during the 10-year study period.
Fosfomycin (FOS) susceptibility testing was performed for 17.77% of outpatient and 21.23% of inpatient
isolates, respectively. Overall, the ratio of resistant strains was 30.33% (outpatients) and 18.69%
(inpatients) (p = 0.023).
3. Discussion
Compared with UTIs caused by other relevant bacterial pathogens, UTIs caused by Proteae are often
more severe and associated with a higher incidence of recurrence, sequelae, and pyelonephritis [13,14].
In addition, the majority of bloodstream infections caused by Proteae members originate from a UTI
(urosepsis), frequently associated with urinary catheters and underlying conditions [35]. Increased
resistance levels to antimicrobial agents are not only leading to changes in treatment guidelines and
issues in the clinic, but also to poor prognoses, decreased QoL and an increase in the mortality rate of
patients, especially in nosocomial settings [1–6]. Treatment of Proteae infections is especially challenging
due to the various intrinsic resistance mechanisms they possess [13,14]. Other last-resort drugs used
in severe infections with Gram-negative pathogens, like tigecycline and colistin are not useful in the
therapy of Proteae-associated pathologies [36,37]. Several reports on the emergence and spread MDR
Proteus and related species have also been published, which is further cause for concern [38,39]. This
study presents the changing epidemiology and resistance trends of Proteae associated with urinary
tract infections (UTIs) in Hungary over a long surveillance period (10 years), demonstrating a steady
increase in the resistance levels regarding various antibiotics. To the best of our knowledge, this is the
first and longest-spanning study reporting on the prevalence and susceptibility patterns of Proteae (and
UTIs caused by these uropathogens by proxy) in Hungary.
The members of the Proteae tribe were causative agents in UTIs in around 5% of cases for outpatient
and 7% in inpatient settings, and, therefore, their clinical relevance should not be disregarded [13,14,35].
Based on the results of this retrospective survey, the most prevalent isolate at our tertiary-care center
remains P. mirabilis; however, a noteworthy increase (~5–7-times higher) was observed in the isolation
rate of Morganella and Providencia species in the second half of the study period. Their higher prevalence
in hospitalized patients and catheter-associated infections, a slight male dominance (~1.1–1.5-times)
and the advanced age (over 65 years of age) of many affected patients is in line with the findings in the
literature [13,14,17–19,24]. There is great variation in the species-distribution and susceptibilities of
urinary tract pathogens in various parts of the globe, and, therefore, continuous and strict surveillance
is recommended [40]. Based on relevant studies in the same geographical region (Southern Great
Plain of Hungary), members of Proteae (especially P. mirabilis) are the third most commonly isolated
microorganisms (E. coli and Klebsiella spp. were the most common, while after Proteae, non-fermenting
Gram-negative bacteria, members of the CES group (Citrobacter-Enterobacter-Serratia) and Candida spp.
were the most prevalent) [41,42]. In another study from Hungary (concentrating on the region near
the capital) Proteae were isolated from 3–9% of urine samples; the resistance rates of these pathogens
were the following: fluoroquinolones 10–50%, aminoglycosides 0–38%, ceftriaxone 0–9%, SMX/TMP
20–53%, and fosfomycin 0–14% [31]. Global reports suggest that overall, P. mirabilis is the fourth
most common pathogen in UTIs, with an estimated prevalence of 2–2.8% [3]. The global SMART
study, published by Morrissey et al., reported P. mirabilis in 3.6% of isolates (fourth most common);
in this study, the ESBL-positivity for these bacteria were ~8% in the US, ~12% in Europe and >40%
in some parts of Asia [25]. In a separate arm of the SMART study in Latin America, Ponce-de-Leon
et al. reported 2% of Proteus isolates as ESBL-positive, while ceftriaxone, levofloxacin, and amikacin
susceptibilities were 92%, 89%, and 100%, respectively [27]. In a study by Stefaniuk et al. in Poland,
this was further verified, as the reported prevalence of Proteus spp. was 7.6% (2.8% in uncomplicated
infections, while 13.5% in complicated UTIs), with a similar pattern of resistance trends as in the
present study [5]. In a study from New York State, Rank et al. reported Proteae as the group fourth
most common uropathogens, with the following susceptibility rates: SMX/TMP 87.0%, ciprofloxacin
84.0%, ceftazidime 93.0%, and tobramycin 95.0% [43]. In contrast, Yang et al. reported Proteae as the
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third most common UTI pathogen group in a tertiary-care hospital in China; the resistance rates of
these isolates were 8.6–9.8% for amikacin, 12.1–14.6% for levofloxacin [33].
The role of the diagnostic bacteriology laboratories is to supply clinically relevant information
in a precise and timely manner, which should be reciprocated by the feedback of the physicians,
starting from the sample submission, followed by information regarding the symptoms of the patient
and the clinical presentation [44]. Our local resistance results reflect the global pattern of increasing
drug resistance in Proteae towards a variety of antimicrobial agents. It also highlights the importance
of continuous surveillance at a local level in order to guide treatment recommendations for local
use [43]. The results of this study suggest that—in most cases—empiric therapy for Proteae UTIs is not
recommended, as the resistance rates (both for inpatient and outpatient samples) was over 20% for all
of the tested drugs. Based on international guidelines, empiric antibiotic therapy is not recommended
with a drug, where local resistance rates exceed 20% (in some cases 10%) [24,45]. In addition, the
consultation with a hospital cumulative antibiogram (if it exists) is of the utmost importance, before
the final choice of antimicrobial therapy [46]. The resistance developments of Proteae, coupled with
their intrinsic non-susceptibility to several drug groups, severely limits the number of therapeutic
alternatives, especially for outpatients. As a general rule, fosfomycin (if susceptibility is confirmed)
still represents a safe and viable alternative for the therapy of these infections [47].
The indole-negative P. mirabilis strains are generally more susceptible to the relevant antibiotics
than P. vulgaris (and other related species), Morganella spp., and Providencia spp [13,14,17–19,24];
however, this difference in resistance rates was not demonstrated in our present study. Gentamicin
resistance has remained relatively constant in the surveillance period, while other antibiotics, which
are more frequently used in primary care (especially amoxicillin/clavulanic acid, ciprofloxacin,
sulfamethoxazole/trimethoprim, and fosfomycin) or are available in oral formulations, resistance levels
show a pronounced and statistically significant increase [48]. Resistance rates for amoxicillin/clavulanic
acid in P. mirabilis were two times higher in inpatient and six times higher in outpatient samples from
baseline resistance values. Ciprofloxacin resistance rates were two times higher in inpatients and
4.5 times higher in outpatient from baseline resistance levels. Similarly, high levels of fluoroquinolone
resistance have been reported for Proteae in regions where there are no restrictions and they are still
considered to be first-line agents [49–52]. Quantitatively, antibiotic utilization levels in Hungary
are relatively good; however, the qualitative analysis reveals a much bleaker picture: The use
of broad-spectrum antimicrobials (including fluoroquinolones) is significantly higher, which may
correspond to the development of local resistance trends [48,53,54]. Interestingly, while the ratio of
resistant isolates from inpatient samples was significantly higher, the increase in the ratio of resistant
strains over time was actually more pronounced in the isolates from outpatient samples.
Based on the results of our study, the most concerning development is the resistance rates to
third-generation cephalosporins (during our study ceftriaxone was chosen as an indicator; however, the
group also includes cefotaxime, ceftriaxone, ceftazidime, and cefoperazone) [55]. Ceftriaxone-resistance
rates have increased by three times in inpatient samples, and by almost ten times in outpatient samples.
Resistance to β-lactam antibiotics is a severe issue in Proteae infections, especially in vulnerable
patient groups (e.g., pregnant women, children), where some other therapeutic alternatives are
inappropriate due to their teratogenicity. Resistance to third-generation cephalosporins (16.18–48.70%
for inpatients and 4.05–38.14% for outpatients) in Proteae is mainly mediated through the production
of ESBLs or AmpC β-lactamases [13,14,17–19,24]. Until recently, the detection of extended-spectrum
beta-lactamase (ESBL)-producing isolates in Proteae was only recommended from blood culture isolates,
and for public health purposes by EUCAST; however, this recommendation has been revised in 2017
(http://www.eucast.org/resistance_mechanisms/). Since this study reports on the resistance trends
of Proteae between 2008–2017, the exact (molecular) identification of the β-lactam (i.e., ceftriaxone)
resistance mechanism was, therefore, not performed during the study period. Additionally, this task
was mainly carried out by a reference laboratory in Hungary for monetary considerations, and for
invasive isolates only. Although the exact ratio of ESBL-positive CRO-resistant strains is unknown,
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there is literature data available, reporting that the ESBL-positivity rates are one of the lowest in Proteae
(Klebsiella > Escherichia > Enterobacter > Proteus > Morganella > Providencia) [56]. In Hungary, since the
2000s, the most prevalent (>95%) type of ESBL-enzymes are the blaCTX-M-type beta-lactamases, which
practically ousted most of the other types of ESBL-enzymes [57].
When it comes to carbapenems, it is well-known that imipenem is only marginally effective
against Proteae. No meropenem-resistant strains were detected, therefore, in an inpatient setting (or
through the utilization of outpatient parenteral antimicrobial therapy; OPAT) meropenem may be a
safe option for now [58]. However, hospitalization in itself also carries a number of risks (e.g., acquiring
nosocomial infections), especially in severely debilitated, immunocompromised patients. Nevertheless,
this selection pressure will probably aid the emergence and global spread of carbapenemase-producing
Enterobacteriaceae (CPE) even further, adding to the crisis of antimicrobial resistance [10]. However,
if global resistance developments are any indication, Hungary will not avoid the increasing prevalence
of MDR Proteae.
Some limitations of this study must be acknowledged. Firstly, the design of this study is
retrospective and, due to the inability to access the medical records of the individual patients
affected, the correlation between the existence of relevant risk factors and underlying illnesses (apart
from age, inpatient/outpatient status, and catheterization) and Proteae UTIs could not be assessed.
The age-associated incidence in isolation of Proteae may also reflect (at least in part) the high rate of
bacteriuria in the elderly population. Furthermore, phenotypic verification of the causes of β-lactam
(ceftriaxone) resistance (AmpC- or ESBL-enzymes, porin loss, changes in permeability or other) or
the molecular characterization of the genetic background of resistance (by PCR or sequencing) in the
individual isolates was not performed, due to financial constraints, and previous local guidelines.
There is a risk of selection bias, as most studies describing the prevalence of infectious diseases
are tertiary-care centers, which generally corresponds to patients with more severe conditions or
underlying illnesses.
4. Materials and Methods
4.1. Study Design, Data Collection
This retrospective study was carried out using microbiological data collected from the period
between the 1st of January 2008 and 31st of December 2017 at the Albert Szent-Györgyi Clinical
Center, a university-affiliated (University of Szeged), primary- and tertiary-care teaching hospital in the
Southern Great Plain of Hungary. The Clinical Center has a bed capacity of 1820 beds (1465 active and
355 chronic beds, respectively) and annually serves more than 400,000 patients in the region (based on
the data of the National Health Insurance Fund) (Figure 3) [59]. An electronic search in the records of
the MedBakter laboratory information system (LIS) for urine samples submitted with the suspicion of a
urinary tract infection was conducted by the authors (M.G. and E.U.). Samples with clinically significant
colony counts for Proteae (105< CFU/mL; however, this was subject to interpretation, based on the
information provided on the request forms for microbiological analysis and relevant international
guidelines) were included in the data analysis. Isolates were considered separate if they occurred
more than 14 days apart or isolates with different antibiotic-susceptibility patterns were detected [60].
In addition, patient data limited to demographic characteristics (age and sex) were also collected.
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4.2. Identification of Isolates
10 µL of each un-centrifuged urine sample was cultured on UriSelect chromogenic agar plates
(Bio-Rad, Berkeley, CA, USA) with a calibrated loop, according to the manufacturer’s instructions and
incubated at 37 ◦C for 24–48 hours, aerobically. If the relevant pathogens presented in significant colony
count, the plates were passed on for further processing. Between 2008–2012, presumptive phenotypic
(biochemical reaction-based) methods and VITEK 2 Compact Automated ID/AST System (bioMérieux,
Marcy-l'Étoile, France) were used for bacterial identification, and, after 2013, this was complemented by
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker
Daltonik Gmbh. Gr.). The methodology of sample preparation for MALDI-TOF MS measurements
was described elsewhere [61]. Mass spectrometry was performed by the Microflex MALDI Biotyper
(Bruker Daltonics, Germany) in positive linear mode across the m/z range of 2 to 20 kDa; for each
spectrum, 240 laser shots at 60 Hz in groups of 40 shots per sampling area were collected. The MALDI
Biotyper RTC 3.1 software (Bruker Daltonics, Germany) and the MALDI Biotyper Library 3.1 were
used for spectrum analysis.
4.3. Antimicrobial Susceptibility Testing
Antimicrobial susceptibility testing (AST) was performed using the Kirby–Bauer disk diffusion
method and E-test (Liofilchem, Abruzzo, Italy) on Mueller–Hinton agar (MHA) plates. In addition, for
the verification of discrepant results, VITEK 2 Compact Automated ID/AST System (Gr- AST card)
(bioMérieux, Marcy-l'Étoile, France) was also utilized. The interpretation of the results was based on
EUCAST breakpoints (http://www.eucast.org). Staphylococcus aureus ATCC 29213, Enterococcus faecalis
ATCC 29212, Proteus mirabilis ATCC 35659, Escherichia coli ATCC 25922 and Pseudomonas aeruginosa
ATCC 27853 were used as quality control strains.
To evaluate the resistance trends of isolated strains, amoxicillin/clavulanic acid (AMC),
ceftriaxone (CRO), meropenem (MER), ertapenem (ERT), gentamicin (GEN), ciprofloxacin (CIP),
sulfamethoxazole/trimethoprim (SXT), and fosfomycin (FOS) were chosen as indicator antibiotics,
based on local antibiotic utilization data [62–65]. AMC resistance data was collected for P. mirabilis
only (as most other members of Proteae are intrinsically resistant) [14]. Susceptibility testing data for
fosfomycin (FOS) was available from 2012; FOS susceptibility testing was not routinely performed,
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only in cases of extensive drug resistance or per request of the clinicians [66]. During data analysis,
intermediately-susceptible results were grouped with and reported as resistant.
4.4. Statistical Analysis
Descriptive statistical analysis (including means or medians with ranges and percentages to
characterize data) was performed using Microsoft Excel 2013 (Redmond, WA, Microsoft Corp.).
Statistical analyses were performed with SPSS software version 24 (IBM SPSS Statistics for Windows 24.0,
Armonk, NY, IBM Corp.), using the χ2-test, Student’s t-test and Mann–Whitney U test. The normality of
variables was tested using Shapiro–Wilk tests. P values < 0.05 were considered statistically significant.
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